Interrogating open issues in cancer precision medicine with patient-derived xenografts

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	BYRNE Annette T. ALFEREZ Denis G. AMANT Fréderic ANNIBALI Daniela ARRIBAS Joaquín BIANKIN Andrew V. BRUNA Alejandra BUDINSKÁ Eva CALDAS Carlo CHANG David K. CLARKE Robert B. CLEVERS Hans COUKOS George DANGLES-MARIE Virginie ECKHARDT S. Gail GONZALEZ-SUAREZ Eva HERMANS Els HIDALGO Manuel JARZABEK Monica A. JONG Steven de JONKERS Jos KEMPER Kristel LANFRANCONE Luisa MAELANDSMO Gunhild Mari MARANGONI Elisabetta MARINE Jean-Christophe MEDICO Enzo NORUM Jens Henrik PALMER Héctor G. PEEPER Daniel S. PELICCI Pier Giuseppe PIRIS-GIMENEZ Alejandro ROMAN-ROMAN Sergio RUEDA Oscar M. SEOANE Joan SERRA Violeta SOUCEK Laura VANHECKE Dominique VILLANUEVA Alberto VINOLO Emilie BERTOTTI Andrea TRUSOLINO Livio
Year of publication	2017
Type	Article in Periodical
Magazine / Source	NATURE REVIEWS CANCER
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1038/nrc.2016.140
Field	Oncology and hematology
Keywords	patient-derived xenografts
Attached files	Interrogating.pdf
Description	Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective ofEurOPDX, an international initiative devoted to PDX-based research.
Related projects:	Výzkumná infrastruktura RECETOX CETOCOEN Plus